Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestogen presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception for women of reproductive age.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert is a hormonal intrauterine system used for contraception in women of reproductive age.

Contraception: Provides long‑acting reversible contraception to prevent pregnancy. Menstrual regulation: Reduces heavy menstrual bleeding associated with hormonal contraception. Endometrial suppression: Inhibits endometrial proliferation to maintain contraceptive efficacy.

Levosert may cause a range of local and systemic reactions after insertion.

Common Side Effects: - Irregular bleeding or spotting during the first months. - Amenorrhea after continued use. - Cramping or pelvic pain at insertion. - Headache or mild nausea. - Breast tenderness. - Vaginal discharge.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device. - Pelvic inflammatory infection. - Ectopic pregnancy if contraception fails. - Allergic reaction to device components. - Severe abdominal pain requiring medical evaluation.

Before using Levosert, clinicians should assess patient suitability and counsel on potential risks.

Contraindications: Pregnancy, known or suspected uterine anomalies, active pelvic infection, or breast cancer. Screening: Verify negative pregnancy test prior to insertion. Follow‑up: Check device position 4–6 weeks after placement. Bleeding changes: Counsel patients that irregular bleeding is common initially. Concurrent hormonal therapy: Avoid overlapping use of other hormonal contraceptives. Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Levosert has limited systemic absorption, but certain drugs can affect levonorgestrel levels.

Major Interactions (Avoid): - Rifampicin or other strong enzyme inducers: may reduce levonorgestrel efficacy. - Anticonvulsants such as carbamazepine, phenytoin: can lower hormone concentrations. - Mifepristone: may antagonize progestogenic activity.

Moderate Interactions (Monitor Closely): - St. John’s wort: may decrease levonorgestrel levels. - Azole antifungals (ketoconazole, itraconazole): may increase hormone exposure. - HIV protease inhibitors: potential alteration of hormone metabolism requiring monitoring.